These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32866170)

  • 21. Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.
    Scherr N; Pluschke G; Thompson CJ; Ramón-García S
    PLoS Negl Trop Dis; 2015 Aug; 9(8):e0003996. PubMed ID: 26270480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activity of avermectins against Mycobacterium ulcerans.
    Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic management of
    Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.
    Martins TG; Trigo G; Fraga AG; Gama JB; Longatto-Filho A; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS Negl Trop Dis; 2012; 6(11):e1925. PubMed ID: 23209864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
    Fukano H; Nakanaga K; Goto M; Yoshida M; Ishii N; Hoshino Y
    PLoS One; 2022; 17(10):e0274742. PubMed ID: 36201529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth.
    Adusumilli S; Haydel SE
    BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.
    Martins TG; Gama JB; Fraga AG; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS One; 2012; 7(2):e32740. PubMed ID: 22393444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
    Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
    Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
    Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
    Guarner J
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
    Arenaz-Callao MP; González Del Río R; Lucía Quintana A; Thompson CJ; Mendoza-Losana A; Ramón-García S
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007126. PubMed ID: 30689630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND; Athan E; Walton AL; O'Brien DP
    Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buruli ulcer in West Africa: strategies for early detection and treatment in the antibiotic era.
    Webb BJ; Hauck FR; Houp E; Portaels F
    East Afr J Public Health; 2009 Aug; 6(2):144-7. PubMed ID: 20000019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
    Sarfo FS; Phillips R; Asiedu K; Ampadu E; Bobi N; Adentwe E; Lartey A; Tetteh I; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3678-85. PubMed ID: 20566765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.